Autoantibodies: Potential clinical applications in early detection of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma

Table 3 Diagnostic performance of single tumor-associated autoantibody biomarkers in esophagogastric junction adenocarcinoma

Target antigen of auto-anti-bodies	Authors, year	EGJA cases, n	Stage, n					Con-trols, n	P value	Sensiti-vity, all stages/ early stage	Specifi-city, all stages/ early stage	AUC, all stages/ early stage	Method
			I	II	III	IV	Tx
p53	Xu et al[42], 2019	122 (Train-ing)	2	16	87	17	122	169 (Valida-tion)	< 0.0001	35.2%/ 33.3%	90.5%/ 90.5%	0.718/ 0.648	ELISA
		70 (Train-ing)	11	14	30	15	80	80 (Valida-tion)	< 0.0001	35.7%/ 40.0%	96.3%/ 96.3%	0.766/ 0.799	ELISA
	Zhou et al[41], 2015	75	-	-	-	-	75	140	< 0.001	24.0%/-	92%/-	0.67/-	ELISA
NY-ESO-1	Xu et al[42], 2019	122 (Train-ing)	2	16	87	17	122	169 (Valida-tion)	< 0.0001	37.7%/ 27.8%	90.5%/ 90.5%	0.718/ 0.654	ELISA
		70 (Train-ing)	11	14	30	15	80	80 (Valida-tion)	< 0.0001	34.3%/ 28.0%	95.0%/ 95.0%	0.747/ 0.714	ELISA
PRDX6	Xu et al[42], 2019	122 (Train-ing)	2	16	87	17	122	169 (Valida-tion)	0.033	34.4%/ 38.9%	90.5%/ 90.5%	0.573/ 0.602	ELISA
		70 (Train-ing)	11	14	30	15	80	80 (Valida-tion)	0.002	30.0%/ 28.0%	90.0%/ 90.0%	0.647/ 0.629	ELISA
MMP-7	Xu et al[42], 2019	122 (Train-ing)	2	16	87	17	122	169 (Valida-tion)	0.005	30.3%/ 33.3%	90.5%/ 90.5%	0.597/ 0.575	ELISA
		70 (Train-ing)	11	14	30	15	80	80 (Valida-tion)	0.036	24.3%/ 28.0%	95.0%/ 95.0%	0.599/ 0.609	ELISA
Hsp70	Xu et al[42], 2019	122 (Train-ing)	2	16	87	17	122	169 (Valida-tion)	< 0.0001	18.0%/ 16.7%	90.5%/ 90.5%	0.652/ 0.697	ELISA
		70 (Train-ing)	11	14	30	15	80	80 (Valida-tion)	< 0.0001	28.6%/ 32.0%	86.3%/ 86.3%	0.686/ 0.702	ELISA
Bmi-1	Xu et al[42], 2019	122 (Train-ing)	2	16	87	17	122	169 (Valida-tion)	< 0.0001	22.1%/ 27.8%	90.5%/ 90.5%	0.686/ 0.685	ELISA
		70 (Train-ing)	11	14	30	15	80	80 (Valida-tion)	< 0.0001	54.3%/ 40.0%	90.0%/ 90.0%	0.711/ 0.682	ELISA
Koc	Zhou et al[41], 2015	75	-	-	-	-	75	140	0.05	19.0%/-	91%/-	-	ELISA
P62	Zhou et al[41], 2015	75	-	-	-	-	75	140	0.02	16.0%/-	94%/-	-	ELISA
C-Myc	Zhou et al[41], 2015	75	-	-	-	-	75	140	0.18	11.0%/-	94%/-	-	ELISA
IMP1	Zhou et al[41], 2015	75	-	-	-	-	75	140	0.04	13.0%/-	95%/-	-	ELISA
Survivin	Zhou et al[41], 2015	75	-	-	-	-	75	140	0.002	17.0%/-	96%/-	-	ELISA
P16	Zhou et al[41], 2015	75	-	-	-	-	75	140	0.01	15.0%/-	96%/-	-	ELISA
Cyclin B1	Zhou et al[41], 2015	75	-	-	-	-	75	140	0.01	12.0%/-	97%/-	-	ELISA

EGJA: Esophagogastric junction adenocarcinoma; AUC: Area under the curve; PRDX 6: Peroxiredoxin 6; Mmp-7: Matrix metallopeptidase 7; Hsp70: Heat shock protein 70; Bmi-1: BMI1 proto-oncogene, polycomb ring finger; Koc: Insulin-like growth factor 2 mRNA binding protein 3; C-Myc: MYC proto-oncogene, bHLH transcription factor; IMP1: Insulin-like growth factor 2 mRNA binding protein 1.